British American Tobacco Invests $176.6 Million In Organigram And Will Develop CBD Products
They will each have access to each other’s intellectual property.
Organigram Holdings Inc’s U.S.-listed shares soared 47% in premarket trade Thursday, after the Canadian cannabis company said it has received a C$221 million ($176.6 million) investment from a unit of British American Tobacco PLC. The tobacco company has subscribed for about 58.3 million shares of Organigram, equal to a 19.9% stake at a price per share of C$3.792, based on a five-day volume weighted average price on the TSX ending March 9, 2021.
Organigram shares closed Wednesday at $2.89. As part of the deal, the companies have entered a product development collaboration agreement, and will create a Center of Excellence to work together to develop the next generation of cannabis products, focused initially on CBD. “Both companies will contribute scientists, researchers, and product developers to the Center of Excellence which will be governed and supervised by a steering committee,” the two companies said in a statement.
To Read The Rest Of This Article On Market Watch, Click Here
